IntroductionImaging genetic studies provide for the possibility to uncover endophenotypes for neuropsychiatric disorders.ObjectivesTo establish neuroimaging correlates of the joint effect of serotonergic (5-HTTLPR) and dopaminergic (COMT) genes.AimsTo examine an interaction of 5-HTTLPR and COMT markers on effective connectivity and regional brain volume in healthy individuals.MethodsNinety one healthy Caucasian adults underwent functional magnetic resonance imaging (fMRI) and structural MRI. In fMRI study the participants were presented with videoclips of dynamic emotional facial expressions of fear, sadness, happiness and anger. The effective connectivity within the emotion processing circuitry was assessed with Granger causality method. In the structural neuroimaging part of the study we applied diffeomorphic anatomic registration through exponentiated Lie algebra (DARTEL) whole-brain voxel-based morphometry (VBM).ResultsIn fear processing condition, an interaction between 5-HTTLPR (S) and COMT(met) low activity alleles was associated with reduced effective connectivity within the facial emotion processing circuitry.The results of the structural data analysis showed an interaction of COMT and 5-HTTLPR genotypes with regional grey matter volume in bilateral parahippocampal gyrus, amygdala, hippocampus, cerebellum and right putamen. In particular, the gray matter volume in these regions was smaller in individuals who were both COMT-met and 5-HTTLPR-S carriers, as compared to those carrying either 5-HTTLPR-L/L, or COMT-val/val.ConclusionsThe epistatic effect of COMT-met and 5-HTTLPR-S markers impacts on both the brain function and structure and may underlie an inefficient emotion regulation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.